NO311132B1 - Nye diosmetinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske preparater inneholdende dem - Google Patents
Nye diosmetinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske preparater inneholdende dem Download PDFInfo
- Publication number
- NO311132B1 NO311132B1 NO19954173A NO954173A NO311132B1 NO 311132 B1 NO311132 B1 NO 311132B1 NO 19954173 A NO19954173 A NO 19954173A NO 954173 A NO954173 A NO 954173A NO 311132 B1 NO311132 B1 NO 311132B1
- Authority
- NO
- Norway
- Prior art keywords
- hydroxy
- benzopyran
- formula
- compound
- methoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 209
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 title claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- -1 2,3-dihydroxypropyl Chemical group 0.000 claims abstract description 77
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 18
- MBNGWHIJMBWFHU-UHFFFAOYSA-N diosmetin Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MBNGWHIJMBWFHU-UHFFFAOYSA-N 0.000 claims abstract description 15
- QAGGICSUEVNSGH-UHFFFAOYSA-N Diosmetin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 QAGGICSUEVNSGH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001876 diosmetin Drugs 0.000 claims abstract description 13
- 235000015428 diosmetin Nutrition 0.000 claims abstract description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 12
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims abstract description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 150000003254 radicals Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 9
- RRDTUDGILGUTNU-UHFFFAOYSA-N (2,2-dimethyl-1,3-dioxol-4-yl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1=COC(C)(C)O1 RRDTUDGILGUTNU-UHFFFAOYSA-N 0.000 claims description 7
- 238000005984 hydrogenation reaction Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000017105 transposition Effects 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 201000002816 chronic venous insufficiency Diseases 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000002282 venous insufficiency Diseases 0.000 claims description 4
- BNTZUCBRIKFMEA-UHFFFAOYSA-N 6-[3-[7-(2,3-dihydroxypropoxy)-5-hydroxy-4-oxochromen-2-yl]-6-methoxy-2-propylphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound COC1=CC=C(C=2OC3=CC(OCC(O)CO)=CC(O)=C3C(=O)C=2)C(CCC)=C1OC1OC(C(O)=O)C(O)C(O)C1O BNTZUCBRIKFMEA-UHFFFAOYSA-N 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 2
- YSACEBNORXLLMY-UHFFFAOYSA-N 5,7-bis(2,3-dihydroxypropoxy)-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(OCC(O)CO)C=C(OCC(O)CO)C=C2O1 YSACEBNORXLLMY-UHFFFAOYSA-N 0.000 claims description 2
- WXIULBFEGRXFEQ-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-6,8-dipropylchromen-4-one Chemical compound C=1C(=O)C2=C(O)C(CCC)=C(O)C(CCC)=C2OC=1C1=CC=C(OC)C(O)=C1CCC WXIULBFEGRXFEQ-UHFFFAOYSA-N 0.000 claims description 2
- MCEUWFUKBYEYRV-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)-2-[3-(2,3-dihydroxypropoxy)-4-methoxyphenyl]-5-hydroxychromen-4-one Chemical compound C1=C(OCC(O)CO)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OCC(O)CO)C=C2O1 MCEUWFUKBYEYRV-UHFFFAOYSA-N 0.000 claims description 2
- RERBSIUIWUEXQO-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)-5-hydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-6-propylchromen-4-one Chemical compound C=1C(=O)C2=C(O)C(CCC)=C(OCC(O)CO)C=C2OC=1C1=CC=C(OC)C(O)=C1CCC RERBSIUIWUEXQO-UHFFFAOYSA-N 0.000 claims description 2
- HDQARNJPLNCMEB-GFCCVEGCSA-N 7-[(2r)-2,3-dihydroxypropoxy]-5-hydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)chromen-4-one Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC[C@H](O)CO)C=C2O1 HDQARNJPLNCMEB-GFCCVEGCSA-N 0.000 claims description 2
- HDQARNJPLNCMEB-LBPRGKRZSA-N 7-[(2s)-2,3-dihydroxypropoxy]-5-hydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)chromen-4-one Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC[C@@H](O)CO)C=C2O1 HDQARNJPLNCMEB-LBPRGKRZSA-N 0.000 claims description 2
- OTAFHZMPRISVEM-UHFFFAOYSA-N benzo-gamma-pyrone Natural products C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 claims description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- ZGAKITWAHUVFTO-UHFFFAOYSA-N [5-[7-(2,3-dihydroxypropoxy)-5-hydroxy-4-oxochromen-2-yl]-2-methoxyphenyl] 2,2-dimethylpropanoate Chemical compound C1=C(OC(=O)C(C)(C)C)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OCC(O)CO)C=C2O1 ZGAKITWAHUVFTO-UHFFFAOYSA-N 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 abstract 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 90
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- 239000000203 mixture Substances 0.000 description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- 238000001953 recrystallisation Methods 0.000 description 32
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 27
- 239000002904 solvent Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 238000003756 stirring Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000000538 analytical sample Substances 0.000 description 13
- 239000003480 eluent Substances 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000004821 distillation Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 235000015497 potassium bicarbonate Nutrition 0.000 description 7
- 239000011736 potassium bicarbonate Substances 0.000 description 7
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 7
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 206010015866 Extravasation Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000036251 extravasation Effects 0.000 description 5
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- XEMICOQRVLYJMM-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)chromen-4-one Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 XEMICOQRVLYJMM-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RELMFMZEBKVZJC-UHFFFAOYSA-N 1,2,3-trichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1Cl RELMFMZEBKVZJC-UHFFFAOYSA-N 0.000 description 2
- XBTLHJXCIVMMCC-UHFFFAOYSA-N 2-[3-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-4-methoxyphenyl]-5,7-dihydroxychromen-4-one Chemical compound COC1=CC=C(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)C=C1OCC1=COC(C)(C)O1 XBTLHJXCIVMMCC-UHFFFAOYSA-N 0.000 description 2
- GVVROHHTQIAMRH-UHFFFAOYSA-N 5,7-bis[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=CC(OCC=2OC(C)(C)OC=2)=C2)=CC(=O)C1=C2OCC1=COC(C)(C)O1 GVVROHHTQIAMRH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GHWFRKYFIMDJNB-UHFFFAOYSA-N 2-(3,4-dimethoxy-2-propylphenyl)-7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-methoxychromen-4-one Chemical compound CCCC1=C(OC)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(OC)C=C2OCC1=COC(C)(C)O1 GHWFRKYFIMDJNB-UHFFFAOYSA-N 0.000 description 1
- BZNPFWSNGOARMN-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-hydroxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OCC1=COC(C)(C)O1 BZNPFWSNGOARMN-UHFFFAOYSA-N 0.000 description 1
- XJCQMFUCQDUSSG-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-methoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(OC)C=C2OCC1=COC(C)(C)O1 XJCQMFUCQDUSSG-UHFFFAOYSA-N 0.000 description 1
- KHABLWKPCRHIFB-UHFFFAOYSA-N 2-(4-methoxy-3-prop-2-ynoxyphenyl)-5,7-bis(prop-2-ynoxy)chromen-4-one Chemical compound C1=C(OCC#C)C(OC)=CC=C1C1=CC(=O)C2=C(OCC#C)C=C(OCC#C)C=C2O1 KHABLWKPCRHIFB-UHFFFAOYSA-N 0.000 description 1
- BJCQZTBODFZRDA-UHFFFAOYSA-N 2-[3-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-4-methoxyphenyl]-5-hydroxy-7-phenylmethoxychromen-4-one Chemical compound COC1=CC=C(C=2OC3=CC(OCC=4C=CC=CC=4)=CC(O)=C3C(=O)C=2)C=C1OCC1=COC(C)(C)O1 BJCQZTBODFZRDA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- DQEAOZUYZXISSN-UHFFFAOYSA-N 5,7-bis(2,3-dihydroxypropoxy)-2-(3-hydroxy-4-methoxy-2-propylphenyl)chromen-4-one Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(OCC(O)CO)C=C(OCC(O)CO)C=C2O1 DQEAOZUYZXISSN-UHFFFAOYSA-N 0.000 description 1
- ZMWKRTPWIXBLSO-UHFFFAOYSA-N 5,7-bis[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-2-(4-methoxy-3-phenylmethoxyphenyl)chromen-4-one Chemical compound COC1=CC=C(C=2OC3=CC(OCC=4OC(C)(C)OC=4)=CC(OCC=4OC(C)(C)OC=4)=C3C(=O)C=2)C=C1OCC1=CC=CC=C1 ZMWKRTPWIXBLSO-UHFFFAOYSA-N 0.000 description 1
- YBNSQSPBODFPCN-UHFFFAOYSA-N 5,7-bis[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-2-[3-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-4-methoxyphenyl]chromen-4-one Chemical compound COC1=CC=C(C=2OC3=CC(OCC=4OC(C)(C)OC=4)=CC(OCC=4OC(C)(C)OC=4)=C3C(=O)C=2)C=C1OCC1=COC(C)(C)O1 YBNSQSPBODFPCN-UHFFFAOYSA-N 0.000 description 1
- KXEUTHWFOLBPDP-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-6-propylchromen-4-one Chemical compound C=1C(=O)C2=C(O)C(CCC)=C(O)C=C2OC=1C1=CC=C(OC)C(O)=C1CCC KXEUTHWFOLBPDP-UHFFFAOYSA-N 0.000 description 1
- YHBFIMQAFDNZHH-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-8-propylchromen-4-one Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(CCC)=C2O1 YHBFIMQAFDNZHH-UHFFFAOYSA-N 0.000 description 1
- QOCCSWNVIJUSAK-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-6-propylchromen-4-one Chemical compound C=1C(=O)C2=C(O)C(CCC)=C(O)C=C2OC=1C1=CC=C(OC)C(O)=C1 QOCCSWNVIJUSAK-UHFFFAOYSA-N 0.000 description 1
- JSXLKPFXMYVBAL-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-8-propylchromen-4-one Chemical compound CCCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(OC)C(O)=C1 JSXLKPFXMYVBAL-UHFFFAOYSA-N 0.000 description 1
- TXAYPSSRADASOG-UHFFFAOYSA-N 5-hydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-7-propoxychromen-4-one Chemical compound C=1C(OCCC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(O)=C1CCC TXAYPSSRADASOG-UHFFFAOYSA-N 0.000 description 1
- UDJDZAXSWMBULI-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)-2-(3,4-dimethoxy-2-propylphenyl)-5-methoxychromen-4-one Chemical compound CCCC1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OCC(O)CO)C=C2O1 UDJDZAXSWMBULI-UHFFFAOYSA-N 0.000 description 1
- ZEXVDUZDMRIXGV-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)-2-(3,4-dimethoxyphenyl)-5-hydroxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OCC(O)CO)C=C2O1 ZEXVDUZDMRIXGV-UHFFFAOYSA-N 0.000 description 1
- RAJLCQCBBVUSKP-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)-2-(3,4-dimethoxyphenyl)-5-methoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OCC(O)CO)C=C2O1 RAJLCQCBBVUSKP-UHFFFAOYSA-N 0.000 description 1
- WOKJNSVEJYTXPP-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)-2-(3-hydroxy-4-methoxy-2-propylphenyl)-5-methoxychromen-4-one Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OCC(O)CO)C=C2O1 WOKJNSVEJYTXPP-UHFFFAOYSA-N 0.000 description 1
- VIFGGTYBXAKJRB-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)-5-hydroxy-2-(4-methoxy-3-propoxyphenyl)chromen-4-one Chemical compound C1=C(OC)C(OCCC)=CC(C=2OC3=CC(OCC(O)CO)=CC(O)=C3C(=O)C=2)=C1 VIFGGTYBXAKJRB-UHFFFAOYSA-N 0.000 description 1
- XCPIJWBKGJRQNT-UHFFFAOYSA-N 7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-2-(3-hydroxy-4-methoxy-2-propylphenyl)-5-methoxychromen-4-one Chemical compound CCCC1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(OC)C=C2OCC1=COC(C)(C)O1 XCPIJWBKGJRQNT-UHFFFAOYSA-N 0.000 description 1
- OCFCESOTBWXBPL-UHFFFAOYSA-N 7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-hydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-6-propylchromen-4-one Chemical compound C1=C2OC(C=3C(=C(O)C(OC)=CC=3)CCC)=CC(=O)C2=C(O)C(CCC)=C1OCC1=COC(C)(C)O1 OCFCESOTBWXBPL-UHFFFAOYSA-N 0.000 description 1
- NBWNKSJQBAOQLB-UHFFFAOYSA-N 7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-hydroxy-2-(4-methoxy-3-phenylmethoxyphenyl)chromen-4-one Chemical compound COC1=CC=C(C=2OC3=CC(OCC=4OC(C)(C)OC=4)=CC(O)=C3C(=O)C=2)C=C1OCC1=CC=CC=C1 NBWNKSJQBAOQLB-UHFFFAOYSA-N 0.000 description 1
- YHVARGMORIFIBV-UHFFFAOYSA-N 7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-hydroxy-2-(4-methoxy-3-propoxyphenyl)chromen-4-one Chemical compound C1=C(OC)C(OCCC)=CC(C=2OC3=CC(OCC=4OC(C)(C)OC=4)=CC(O)=C3C(=O)C=2)=C1 YHVARGMORIFIBV-UHFFFAOYSA-N 0.000 description 1
- FUWBSAWDNNJRTJ-LLVKDONJSA-N 7-[(2r)-2,3-dihydroxypropoxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC[C@H](O)CO)C=C2O1 FUWBSAWDNNJRTJ-LLVKDONJSA-N 0.000 description 1
- FUWBSAWDNNJRTJ-NSHDSACASA-N 7-[(2s)-2,3-dihydroxypropoxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC[C@@H](O)CO)C=C2O1 FUWBSAWDNNJRTJ-NSHDSACASA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- YDWKEUCCRAUKKM-AWEZNQCLSA-N [(2r)-2-hydroxy-3-[5-hydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-4-oxochromen-7-yl]oxypropyl] acetate Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC[C@@H](O)COC(C)=O)C=C2O1 YDWKEUCCRAUKKM-AWEZNQCLSA-N 0.000 description 1
- YDWKEUCCRAUKKM-CQSZACIVSA-N [(2s)-2-hydroxy-3-[5-hydroxy-2-(3-hydroxy-4-methoxy-2-propylphenyl)-4-oxochromen-7-yl]oxypropyl] acetate Chemical compound CCCC1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC[C@H](O)COC(C)=O)C=C2O1 YDWKEUCCRAUKKM-CQSZACIVSA-N 0.000 description 1
- MLNIVWHAPSNYGV-UHFFFAOYSA-N [5-[7-(2,3-dihydroxypropoxy)-5-hydroxy-4-oxochromen-2-yl]-2-methoxyphenyl] 2-methylpropanoate Chemical compound C1=C(OC(=O)C(C)C)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OCC(O)CO)C=C2O1 MLNIVWHAPSNYGV-UHFFFAOYSA-N 0.000 description 1
- DIMLHOFEJKQUIB-UHFFFAOYSA-N [5-[7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-hydroxy-4-oxochromen-2-yl]-2-methoxyphenyl] 2-methylpropanoate Chemical compound C1=C(OC(=O)C(C)C)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OCC1=COC(C)(C)O1 DIMLHOFEJKQUIB-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000012771 intravital microscopy Methods 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- ABXSODXBCMKEND-UHFFFAOYSA-N methyl 3,4,5-triacetyloxy-6-[3-[7-[(2,2-dimethyl-1,3-dioxol-4-yl)methoxy]-5-methoxy-4-oxochromen-2-yl]-6-methoxy-2-propylphenoxy]oxane-2-carboxylate Chemical compound COC1=CC=C(C=2OC3=CC(OCC=4OC(C)(C)OC=4)=CC(OC)=C3C(=O)C=2)C(CCC)=C1OC1OC(C(=O)OC)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O ABXSODXBCMKEND-UHFFFAOYSA-N 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- DITHIFQMPPCBCU-UHFFFAOYSA-N propa-1,2-diene Chemical compound [CH]=C=C DITHIFQMPPCBCU-UHFFFAOYSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9412783A FR2726273B1 (fr) | 1994-10-26 | 1994-10-26 | Nouveaux derives de la diosmetine, leur procede de preparation et les compositions pharmaceutiques les contenant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO954173D0 NO954173D0 (no) | 1995-10-19 |
| NO954173L NO954173L (no) | 1996-04-29 |
| NO311132B1 true NO311132B1 (no) | 2001-10-15 |
Family
ID=9468215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19954173A NO311132B1 (no) | 1994-10-26 | 1995-10-19 | Nye diosmetinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske preparater inneholdende dem |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5629339A (el) |
| EP (1) | EP0709383B1 (el) |
| JP (1) | JP3076231B2 (el) |
| CN (1) | CN1058494C (el) |
| AT (1) | ATE187720T1 (el) |
| AU (1) | AU693599B2 (el) |
| CA (1) | CA2161297C (el) |
| CY (1) | CY2173B1 (el) |
| DE (1) | DE69513935T2 (el) |
| DK (1) | DK0709383T3 (el) |
| ES (1) | ES2145234T3 (el) |
| FI (1) | FI118766B (el) |
| FR (1) | FR2726273B1 (el) |
| GR (1) | GR3032168T3 (el) |
| NO (1) | NO311132B1 (el) |
| NZ (1) | NZ280330A (el) |
| ZA (1) | ZA959076B (el) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2748025B1 (fr) * | 1996-04-25 | 1998-10-30 | Adir | Nouveaux acides et esters de la diosmetine, et les compositions pharmaceutiques les contenant |
| FR2778663B1 (fr) | 1998-05-15 | 2001-05-18 | Coletica | Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire |
| JP2001122791A (ja) * | 1999-10-20 | 2001-05-08 | Boehringer Ingelheim Internatl Gmbh | 下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤 |
| EP1127572A3 (en) * | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
| US20040151769A1 (en) * | 2002-12-31 | 2004-08-05 | Boehringer Ingelheim International Gmbh | Film coated tablet containing an extract of red vine leaves |
| US20040151794A1 (en) * | 2002-12-31 | 2004-08-05 | Boehringer Ingelheim International Gmbh | Method of improvement of blood circulation |
| EP1550450A1 (en) * | 2003-12-29 | 2005-07-06 | Boehringer Ingelheim International GmbH | Composition comprising an aqueous extract of red vine leaves and a blood circulating-improving agent for the treatment of chronic venous insufficiencies |
| EP1718168A1 (en) * | 2004-02-19 | 2006-11-08 | Boehringer Ingelheim International Gmbh | Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves and an anti-inflammatory agent |
| FR2882654B1 (fr) * | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| FR2929276B1 (fr) * | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2017230119A1 (en) * | 2016-03-11 | 2018-09-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Icariin and icaritin derivatives |
| CN109280067B (zh) * | 2017-07-21 | 2022-07-05 | 南京正大天晴制药有限公司 | 香叶木苷衍生物、其制备方法以及医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB928150A (en) * | 1961-02-08 | 1963-06-06 | Upjohn Co | Topical pharmaceutical compositions comprising steroids and flavonoids |
| CH644374A5 (en) * | 1981-05-18 | 1984-07-31 | Espanola Prod Quimicos | Water-soluble hydroxyflavone ethers and medicaments containing them |
| FR2623808B1 (fr) | 1987-12-01 | 1990-03-09 | Adir | Nouveaux derives flavonoides (benzyl-4 piperazinyl-1)-2 oxo-2 ethylene substitues, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2701261B1 (fr) * | 1993-02-05 | 1995-03-31 | Adir | Nouveaux composés glucuronides de la diosmétine, leur procédé de préparation et les compositions pharmaceutiques les renfermant. |
-
1994
- 1994-10-26 FR FR9412783A patent/FR2726273B1/fr not_active Expired - Fee Related
-
1995
- 1995-10-19 NO NO19954173A patent/NO311132B1/no not_active IP Right Cessation
- 1995-10-23 AU AU34404/95A patent/AU693599B2/en not_active Ceased
- 1995-10-24 JP JP07275292A patent/JP3076231B2/ja not_active Expired - Fee Related
- 1995-10-24 CA CA002161297A patent/CA2161297C/fr not_active Expired - Fee Related
- 1995-10-24 US US08/547,650 patent/US5629339A/en not_active Expired - Lifetime
- 1995-10-25 AT AT95402374T patent/ATE187720T1/de active
- 1995-10-25 CN CN95117660A patent/CN1058494C/zh not_active Expired - Fee Related
- 1995-10-25 ES ES95402374T patent/ES2145234T3/es not_active Expired - Lifetime
- 1995-10-25 NZ NZ280330A patent/NZ280330A/en not_active IP Right Cessation
- 1995-10-25 DE DE69513935T patent/DE69513935T2/de not_active Expired - Lifetime
- 1995-10-25 FI FI955085A patent/FI118766B/fi not_active IP Right Cessation
- 1995-10-25 DK DK95402374T patent/DK0709383T3/da active
- 1995-10-25 EP EP95402374A patent/EP0709383B1/fr not_active Expired - Lifetime
- 1995-10-26 ZA ZA959076A patent/ZA959076B/xx unknown
-
1999
- 1999-12-17 GR GR990403253T patent/GR3032168T3/el unknown
-
2000
- 2000-05-30 CY CY0000020A patent/CY2173B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE187720T1 (de) | 2000-01-15 |
| JPH08225563A (ja) | 1996-09-03 |
| NO954173L (no) | 1996-04-29 |
| NO954173D0 (no) | 1995-10-19 |
| FI955085A (fi) | 1996-04-27 |
| AU3440495A (en) | 1996-05-09 |
| ZA959076B (en) | 1996-05-22 |
| DK0709383T3 (da) | 2000-04-25 |
| ES2145234T3 (es) | 2000-07-01 |
| CN1058494C (zh) | 2000-11-15 |
| DE69513935T2 (de) | 2000-07-20 |
| CN1129701A (zh) | 1996-08-28 |
| FR2726273A1 (fr) | 1996-05-03 |
| EP0709383A1 (fr) | 1996-05-01 |
| FI955085A0 (fi) | 1995-10-25 |
| EP0709383B1 (fr) | 1999-12-15 |
| FR2726273B1 (fr) | 1996-12-06 |
| DE69513935D1 (de) | 2000-01-20 |
| JP3076231B2 (ja) | 2000-08-14 |
| FI118766B (fi) | 2008-03-14 |
| GR3032168T3 (en) | 2000-04-27 |
| CY2173B1 (en) | 2002-08-23 |
| NZ280330A (en) | 1996-12-20 |
| CA2161297C (fr) | 2001-10-09 |
| AU693599B2 (en) | 1998-07-02 |
| CA2161297A1 (fr) | 1996-04-27 |
| US5629339A (en) | 1997-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910001042B1 (ko) | 4-아미노알킬-2(3h)-인돌론 및 이의 제조방법 | |
| JPH0216315B2 (el) | ||
| NO311132B1 (no) | Nye diosmetinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske preparater inneholdende dem | |
| JPH024235B2 (el) | ||
| US5665733A (en) | 3-phenylisoquinol-1(2H)-one derivatives their preparation and their therapeutic application | |
| WO2022213931A1 (zh) | 大麻二酚前药及其药物组合物和应用 | |
| EP0205362B1 (fr) | Dérivés quinolylglycinamides, leur procédé de préparation et leur application thérapeutique en tant que psychotropes | |
| JP2733492B2 (ja) | イミダゾピリジン誘導体 | |
| JPS63295566A (ja) | キノキサリノン誘導体 | |
| EP0292400B1 (fr) | Dérivés du Spiro (4,5) décane, leur procédé de préparation et les compositons pharmaceutiques les renfermant | |
| KR100373948B1 (ko) | 호산성과립구의병적인과반응성을감소시키기위한크산틴유도체를포함하는약제학적조성물,신규한크산틴화합물및이의제조방법 | |
| JPS63295561A (ja) | ２−キノロン誘導体 | |
| JPH0559117B2 (el) | ||
| CA2557942A1 (fr) | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique | |
| CN111233820B (zh) | 含有冠醚和二(2-甲氧基乙氧基)结构的芬戈莫德衍生物 | |
| US4797498A (en) | Flavonoxypropanolamines and esters of flavonoxypropanolamines as antiarrhythmic agents | |
| EP0518414B1 (en) | Thioxanthenone antitumor agents | |
| EP0755928B1 (en) | 5-aminoflavone derivatives | |
| JPH0559087A (ja) | ウリジン誘導体及びこれを含有する医薬 | |
| CN112047990B (zh) | 阿糖胞苷前药mb07133晶型及其应用 | |
| JPH0366685A (ja) | イミダゾール誘導体及びそれを有効成分として含有する肝臓疾患治療薬 | |
| DK162089B (da) | 1-phenoxy-3-hydroxyindolylalkylamino-2-propanoler og farmaceutiske praeparater indeholdende disse | |
| CN117924284A (zh) | 一种高效抗病毒化合物及其用途 | |
| JPS6183172A (ja) | ジベンゾ〔ｂ，ｆ〕〔１，５〕オキサゾシン誘導体及びその製造法並びにそれを有効成分とする医薬 | |
| JPS63239223A (ja) | アルドース・リダクターゼ阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |